Metformin as a new anti-cancer drug in adrenocortical carcinoma by Poli, Giada et al.
Oncotarget1www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/ Oncotarget, Advance Publications 2016
INTRODUCTION
Despite its rarity (1:2 million prevalence), 
adrenocortical cancer (ACC) deserves more consideration 
on account of its aggressive behavior and poor prognosis 
when metastatic at diagnosis. To date, the best curative 
option is radical surgery.  In case of advanced ACC, 
mitotane is the only available medical treatment [1, 2]. 
Nevertheless, mitotane has proved to be of limited 
efficacy and poor tolerability, thus often reducing the 
patient’s compliance. The drug’s therapeutic range is 
reached in less than 50% of treated patients [1]; moreover, 
specific polymorphisms of the CYP2B6 gene have been 
associated with reduced circulating levels of mitotane, 
further decreasing its efficacy [3]. The mechanism by 
which mitotane acts on cancer cells, as well as on the 
normal adrenal, is still far from being fully elucidated. 
In such a scenario, it is mandatory to combine mitotane 
with other drugs, in order to improve the therapeutic 
efficacy and reduce treatment toxicity. Of the possible 
drugs that could be associated with mitotane, those safely 
and widely administered for treating other diseases, and 
eventually found to also exert anti-neoplastic effects, 
should offer the best therapeutic option. Metformin 
(1,1-dimethylbiguanide) is a biguanide cationic compound 
commonly used as an insulin-sensitizer and glucose-
lowering drug in the treatment of type 2 diabetes (T2D). 
Epidemiological studies and meta-analyses on large 
cohorts of diabetic patients have demonstrated a significant 
association between metformin and a reduced incidence 
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ABSTRACT
Adrenocortical carcinoma (ACC) is a rare heterogeneous malignancy with poor 
prognosis. Since radical surgery is the only available treatment, more specific and 
effective drugs are urgently required. The anti-diabetic drug metformin has been 
associated with a decreased cancer prevalence and mortality in several solid tumors, 
prompting its possible use for ACC treatment.
This paper evaluates the in vitro and in vivo anti-cancer effects of metformin 
using the ACC cell model H295R.
Metformin treatment significantly reduces cell viability and proliferation in a dose- 
and time-dependent manner and associates with a significant inhibition of ERK1/2 
and mTOR phosphorylation/activation, as well as with stimulation of AMPK activity. 
Metformin also triggers the apoptotic pathway, shown by the decreased expression of 
Bcl-2 and HSP27, HSP60 and HSP70, and enhanced membrane exposure of annexin V, 
resulting in activation of caspase-3 apoptotic effector. Metformin interferes with the 
proliferative autocrine loop of IGF2/IGF-1R, which supports adrenal cancer growth. 
Finally, in the ACC xenograft mouse model, obtained by subcutaneous injection 
of H295R cells, metformin intraperitoneal administration inhibits tumor growth, 
confirmed by the significant reduction of Ki67%.
Our data suggest that metformin inhibits H295R cell growth both in vitro and 
in vivo. Further preclinical studies are necessary to validate the potential anti-cancer 
effect of metformin in patients affected by ACC.
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of various types of solid tumors [4–7], supporting the 
potential use of metformin as an anti-cancer drug [8]. 
Several clinical trials are currently ongoing to specifically 
test metformin efficacy in cancer prevention and therapy 
[9, https://clinicaltrials.gov]. A considerable number 
of studies have demonstrated the anti-cancer activity 
of this drug both in in vitro and in vivo tumor models, 
highlighting a direct anti-proliferative and pro-apoptotic 
effect on cancer cells and an indirect action on metabolic 
regulation [8, 9].
The present paper investigates the in vitro and in 
vivo effects of metformin on the H295R adrenocortical 
cancer cell line.
RESULTS 
Metformin inhibits cell viability and 
proliferation in H295R cells
To investigate the effects of metformin on ACC, 
we first evaluated whether metformin interfered with 
viability in two available ACC cell lines, H295R and 
SW13. In vitro administration of increasing doses of 
metformin resulted in a dose- and time-dependent 
decrease of cell viability, which was statistically 
significant starting from 24 hours, as assessed by 
MTS assay in both the H295R (Figure 1A) and SW13 
(Figure 1B) cell lines. Analysis of MTS dose-response 
curves allowed calculation of metformin inhibitory half 
doses (IC50) for viability. Comparison of the IC50s results 
revealed that the drug had a stronger effect on SW13 than 
H295R cells (Figure 1C, 1D).
Once shown that metformin significantly affected 
viability of both cell lines, we chose to focus on the effects in 
H295R, since this cell model better represents the secreting 
form of ACC. Inhibitory action of metformin was more 
pronounced when assessed by direct cell count (Figure 2A) 
than with MTS analysis; this suggests an additional effect 
on cell proliferation, as further confirmed by thymidine 
incorporation assay (Figure 2B). IC50s were calculated 
from dose-response cell count (Figure 2C) and thymidine 
uptake (Figure 2D) curves for each time point: coherently, 
calculated IC50s decreased with increased treatment time. 
Since in non-tumor cells metformin acts as a 
hypoglycemic drug by facilitating glucose uptake and 
its utilization, we next evaluated these properties in 
the H295R cell line and found that metformin dose-
dependently stimulated a significant increase in cell basal 
glucose uptake (Table 1).
Metformin inhibits ERK and mTOR signaling in 
H295R cells
We next investigated the intracellular signaling 
pathways underlying metformin inhibitory effect on 
H295R growth. We assessed the ability of the drug to 
activate the AMP-activated protein kinase (AMPK) energy 
sensor, via its phosphorylation in the Thr172 residue. 
Western blot analysis of cell lysates showed a significant 
dose-related AMPK phosphorylation stimulation, 
confirming that this intracellular pathway downstream 
from metformin action is also activated in H295R 
(Figure 3A, 3B).
Since in colon cancer metformin exerts an anti-
proliferative effect by suppressing IGF-1R signaling 
[10], we next analyzed the activating phosphorylation 
pattern for Akt and extracellular signal-regulated 
kinases 1/2 (ERK1/2), the two main IGF-1R 
downstream pathways in H295R cells [11]. Increasing 
doses of metformin inhibited phosphorylation of both 
ERK1 and 2 (Figure 3C, 3D), with no significant 
effect on Akt phosphorylation (data not shown). 
Signaling pathways downstream from IGF-1R 
have been shown to converge in mTOR activation to 
sustain cell proliferation in both H295R [12,13] and 
ACC [14]. A 24 hour metformin treatment induced 
a dose-dependent inhibition of mTOR activating 
phosphorylation in the Ser2448 residues (Figure 3E, 3F), 
as well as a significantly lower IGF-1R net expression 
(Figure 3G, 3H).
Metformin activates the apoptotic process in 
H295R cells
To investigate whether the reduced number of 
cells following metformin treatment could be due 
to an enhanced cell death, we next examined the 
cascade of events underlying apoptosis in H295R 
cells. Cytofluorimetric analysis of annexin V exposure 
(Figure 4A), shows that 48 hour treatment of the 
cells with increasing doses of metformin (10, 20, 
50 mM) stimulates a dose-dependent increase in the 
percentage of apoptotic cells, both in early and late 
phases of the apoptotic process, compared with controls 
(Figure 4A, 4B). This finding is associated with a 
significant decrease in the number of living cells. Our 
findings were confirmed by a protein array specifically 
designed to assess the expression of the main proteins 
involved in the apoptotic pathway. H295R cells treated 
with 20 mM metformin for 48 hours expressed lower 
levels of the anti-apoptotic proteins Bcl-2 and Bcl-w, un-
cleaved caspase 3 and heat shock proteins HSP27, HSP60 
and HSP70 (Figure 4C). Decreased IGF2 expression 
was also observed, confirming the inhibitory effect of 
metformin on the autocrine/paracrine IGF2/IGF-1R 
system. Western blot analysis of the same protein extracts 
revealed that 20 mM metformin inhibited Bcl-xl form 
(Figure 4D) and activated caspase-3 by increasing the 
cleaved fragments and decreasing the corresponding un-
cleaved form (Figure 4E).
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Metformin affects tumor growth in vivo in a 
mouse ACC xenograft model
In order to evaluate the in vivo metformin effect, we 
monitored tumor growth in a mouse xenograft ACC model, 
obtained by subcutaneously injecting H295R cells in the 
two groups of athymic CD-1 nude mouse strain [15, 16], 
one treated and one untreated with metformin (3mg/day) 
for 40 days. Metformin administration was associated with 
a statistically significant reduced increase in tumor volume 
after 27 days compared with controls, (Figure 5A). After 
15 days of treatment, the inhibitory effect (1-T/C = 76.2 
± 8.4%) approached the maximum (89.8 ± 6.7%), which 
was reached on day 27th and remained almost constant 
until the animals were sacrificed (80.2 ± 14.0% inhibition 
on day 40th). 
Macroscopically, excided tumors from the control 
group were larger, generally lobulated and highly 
vascularized (Figure 5B) compared with those from the 
treated group, which were smaller and well-circumscribed 
(Figure 5C). 
Histologically, the tumors from the controls 
consisted of rather small, uniform cells with coarse 
chromatin and prominent nucleoli. A haphazard 
network of small-caliber vessels was also observed 
(Figure 5D). Mitotic figures, both typical and atypical, 
were numerous (Figure 5D, asterisks). Conversely, in the 
metformin-treated group, the tumors showed decreased 
vascularization, a greater number of apoptotic bodies 
(arrowheads) and a lower mitotic activity (Figure 5E). 
Foci of necrosis were occasionally seen (Figure 5E). 
Immunohistochemistry demonstrated that tumor 
cells from both the controls (Figure 5F) and metformin-
treated (Figure 5G) mice stained intensely and diffusely 
with SF-1, confirming that they were H295R-derived. 
Metformin treatment (Figure 5I) was associated with a 
Figure 1: Metformin inhibits H295R and SW13 cell viability. Cell viability was assessed by using MTS assay in H295R (A) and 
SW13 (B) cells grown in the presence or absence of increasing doses of metformin (mM) at the indicated time points. Data are expressed as 
mean ± SE of absorbance percentage vs. non-stimulated controls in n = 5 independent experiments. Statistical analysis was performed with 
ANOVA followed by Dunnett’s post hoc test: *P < 0.05, **P < 0.01, §P < 0.0001 vs respective controls. Metformin IC50s for cell viability 
were calculated on the dose-response curves obtained at the indicated time points in H295R (C) and SW13 (D) cell lines.
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reduction in nuclear Ki-67 reactivity, compared to the 
controls (Figure 5H) (Ki-67 mean ± SEM: 55.1 ± 1.8 
vs 74.8 ± 5.2 respectively; P < 0.02; 27% inhibition), 
suggesting an inhibitory effect of metformin on tumor 
proliferation.
Western blot analysis of protein extracts from 
excised tumors confirmed the findings observed in vitro 
in H295R (Figure 3A, 3B and 3E, 3F), that metformin-
in vivo treatment of the xenografted mice was associated 
with an increased level of p-AMPK (Figure 5J) and a 
decreased level of p-mTOR (Figure 5K).
DISCUSSION
Meta-analyses conducted on diabetic subjects 
treated with metformin suggest a decreased incidence of 
several types of cancer [6, 7]. Moreover, preclinical studies 
performed in vitro and in vivo on different types of solid 
tumors [8] have shown that metformin also possesses anti-
tumor properties. In particular, this drug interferes with 
the insulin/IGF-1R system in tumor cells [8, 17] as shown 
in pancreatic [10, 18, 19], breast [20, 21], endometrial 
[22, 23], prostate [24] and lung [25] cancers. Due to the 
rarity of ACC, no data are currently available regarding 
cancer prevalence and metformin treatment in T2D, nor on 
the effect metformin exerts on tumor growth. Our findings 
demonstrate that metformin inhibits proliferation in the 
adrenocortical cancer cell model H295R in association 
with a decreased expression of the IGF2/IGF-1R system. 
ACC is an endocrine tumor where the massive secretion of 
IGF2 acts in an auto/paracrine loop to sustain cancer cell 
proliferation, via activation of both insulin and IGF-1R 
pro-survival intracellular pathways [26–28]. In H295R, 
metformin induces a decrease in IGF2 and IGF-1R 
Figure 2: Metformin affects proliferation in H295R cell line. Cell proliferation was evaluated by direct cell count and thymidine 
incorporation (4 hour pulse) in H295R cells treated in absence or presence of increasing concentrations of metformin (mM) at the indicated 
time points. Data are expressed as mean ± SE of cell count (A) or DNA-thymidine incorporation (B) percentage vs. non-stimulated controls 
in n =3 independent experiments. Metformin IC50s for cell count (C) and thymidine incorporation (D) were calculated on the dose-
response curves obtained at the indicated time points. Statistical analysis was performed with ANOVA followed by Dunnett’s post hoc test: 
§P < 0.001 vs. respective controls.
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expression. The inhibition of IGF-1R promoter activity 
following metformin treatment could involve activation of 
p53, pAMPK and E2F1 transcription factor, which among 
the targets of metformin have been described to regulate 
IGF-1R gene expression [22, 23, 29]. 
In H295R cells, we showed that the drug also 
interferes with the intracellular ERK and mTOR 
signaling pathways downstream from IGF-1R. We 
previously demonstrated that another class of anti-diabetic 
drugs, the thiazolidinediones, including rosiglitazone 
and pioglitazone, inhibits adrenocortical cancer cell 
proliferation [11] and stimulates cell differentiation 
[31, 32]. These drugs also restrained cell proliferation 
through IGF-1R signaling inhibition. However, while 
rosiglitazone acts on inhibition of both pathways, 
metformin seems to mainly affect ERK signaling, with no 
significant effect on phosphorylation/activation of Akt. A 
similar mechanism has been described in granulosa cells, 
where metformin inhibits IGF-1-stimulated cell growth 
through inhibition of ERK signaling and without affecting 
Akt [33]. Furthermore, the key role of ERK1/2 in mediating 
the anti-tumor effect of metformin has been confirmed by 
a xenograft mouse model using neuroblastoma cell lines, 
where a reduced ERK1/2 phosphorylation was observed in 
tumors of metformin-fed mice [34].
The inhibitory effect of metformin on cell growth 
seems due not only to a reduction in cell proliferation 
rate, but also to the stimulation of the mitochondrial-
dependent apoptotic pathway. Indeed, the complex I of 
the mitochondrial respiratory chain is one of the main 
cellular targets of metformin [8]. Metformin inhibition of 
the oxidative phosphorylation (OXPHOS) process reduces 
mitochondrial production of ATP, thus inducing cell energy 
stress and activating the intrinsic apoptotic pathway [8]. In 
H295R cells, we demonstrated that metformin treatment is 
associated with a dose-dependent increase of membrane 
exposure of annexin V, one of the early events in the 
apoptotic cascade. Protein array analysis also showed a 
significant decrease in the expression of the anti-apoptotic 
factors belonging to the family of Bcl-2, the key regulator 
of the intrinsic apoptotic pathway and of mitochondrial 
integrity [35]. Induction of apoptosis finally results in 
the activation of the caspase-3 effector [35], the cleaved 
fragments of which become detectable in H295R cells 
following metformin treatment.
Inhibition of OXOPHOS leads to a reduction in 
the ATP/ADP ratio, thus activating the intracellular key 
energy sensor AMPK [36, 37]. Activated AMPK mainly 
interferes with mTOR activity by disrupting its association 
with mTORC1 [38], finally resulting in a net cytostatic 
effect. In metformin-treated H295R cells, we observed 
an increased AMPK phosphorylation, associated with 
a rapid glucose uptake, which is probably an adaptive 
compensatory mechanism to fuel ATP production through 
glycolysis. However, in breast cancer, mTOR inhibition 
by metformin also blocks glycolytic and tricarboxylic 
acid cycle intermediates necessary for cancer proliferation 
[39], thus interfering with the Warburg effect [40]. 
Similarly, in H295R metformin-induced ERK inhibition 
and AMPK activation may converge in mTOR blockage. 
These findings suggest a metabolic switch from a mainly 
anabolic to a mainly catabolic state to also support energy 
requirements in the H295R cell line. The kinase protein 
mTOR acts as a gatekeeper for metabolism and cell growth, 
catching signals of cell stress, intracellular nutrient levels 
and growth factors [41]. Besides the PI3K/Akt activation 
pathway, which seems unaffected by metformin in H295R, 
mTOR can form an alternative complex with mTORC1 
following ERK1/2 activation [42–44], thus specifically 
mediating the IGF-1/insulin proliferative pathway [12].
Metformin also induces a significant reduction in 
the expression of heat shock proteins (HSPs) involved in 
tumorigenesis [45]. The high rate of anabolic processes 
sustaining cancer cell proliferation and progression in a 
ROS-rich environment requires a high chaperone activity 
to ensure a correct protein folding process. Increased 
HSPs expression has been observed in various types of 
malignancies [46], including adrenocortical cancer [47]. 
In particular, HSP27, 60 and 70 play a pivotal role in 
dampening the apoptotic processes at mitochondrial level 
[45, 48], thus representing promising anti-tumor targets 
for the development of anti-cancer drugs. Here, we have 
demonstrated that metformin treatment leads to reduced 
HSP27/60/70 expression in H295R cells, which may 
contribute to the stimulatory effect of the drug on adrenal 
cancer cell apoptosis.
Table 1: Metformin stimulates glucose uptake in H295R
Metformin (mM) Glucose uptake(% increase) SE P value
0 100.0 5.98 -
10 165.6 6.38 0.000
20 161.8 5.21 0.000
50 126.1 3.19 0.002
The 2-deoxy-[3H] D-glucose uptake was measured in H295R cells treated for 24 hours with metformin and detected as 
radioactive counts per minute (CPM) on a scintillation beta counter. Data are expressed as mean ± SE of percentage increase 
of glucose uptake vs. control without metformin (0 mM). P values obtained by statistical analysis performed with ANOVA 
followed by Dunnett’s post hoc test vs. control are indicated.
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Figure 3: Metformin interferes with ERK and mTOR signaling pathways by activating AMPK. Protein extracts from 
H295R untreated or treated with increasing doses of metformin (20, 50, 100 mM) were analyzed by Western Blot to assess AMPK (A) and 
mTOR (E) phosphorylation after 6 hour treatment, while phospho-ERK1/2 (C) and IGF-1R (G) expression was evaluated after 24 hour 
treatment. For AMPK, mTOR and ERK 1/2 the total protein forms was also evaluated. Bar charts (B, D, F, H) represent mean ± SE band 
intensity of each protein (p-AMPK, p-ERK1/2, p-mTOR, and IGF-1R, respectively) shown as the respective fluorescence intensity of 
Western blot bands normalized on actin, which was used as internal loading control, in at least three independent experiments. Statistical 
analysis was performed with ANOVA followed by Dunnett’s post hoc test: *P < 0.05,**P < 0.005, §P < 0.0001 versus respective controls.
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Figure 4: Metformin stimulates apoptosis in H295R cell line. (A) After 48 hour treatment with increasing doses of metformin 
(Met 10, 20, 50 mM), H295R cells were trypsinized and analyzed with a Muse automated cell analyzer, using the Muse Annexin V/Dead 
Cell Assay. This analysis enabled differentiation, on the basis of annexin V positivity, of four populations of cells for each sample: live, 
early apoptotic, late apoptotic, and dead cells. Cells treated overnight with 0.2 μM staurosporine were used as positive controls of apoptosis 
induction. (B) Bar chart represents mean ± SE of cell percentage for each population identified with Annexin V assay. Mean percentage ± SE 
of total apoptotic cells related to each sample is also indicated above bar charts. Statistical analysis was performed with ANOVA followed 
by Dunnett’s post hoc test: *P < 0.05, **P < 0.001, §P < 0.0001 vs respective controls. (C) Protein array membranes for apoptosis were 
incubated with protein extracts from control (left panel) and 20 mM metformin-treated for 48 hours (right panel) cells. Positive and negative 
spots are indicated, as well as the apoptosis proteins of interest (arrows). (D, E) Western blot analysis of protein extracts from H295R 
treated or untreated with the indicated doses of metformin for 48 hours: treated cells show decreased expression of Bcl-xl and an increase 
in the cleaved active fragments of caspase 3, accompanied by a decrease in the intact form, compared to the control. Actin was used as 
internal protein loading control.
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Figure 5: Metformin inhibits tumor growth in a mouse xenograft model of ACC. ACC xenografts were obtained by H295R 
cell subcutaneous injection in CD1 nude mice and, once tumors had reached a detectable 5 mm diameter, animals were randomized to 
be treated or not with metformin (3 mg/day) for 40 days. Tumor growth was assessed by monitoring the mass volume 3 times a week. 
(A) Tumor growth curves represent mean ± SE of the measured tumor volume over time in control mice (filled squares, n = 5) and 
metformin-treated (filled circles, n = 5) groups. *P < 0.05 between the two groups was obtained by Student’s t test analysis. Analysis of two 
representative tumors excided after 40 day treatment (end of experiment) from both control and treated mice is given: (B, C) macroscopic 
observation; (D, E: 40× magnification) hematoxylin/eosin staining, asterisks and arrowheads indicate mitotic figures and apoptotic bodies, 
respectively; (F, G) immunohistochemistry for SF-1; (H, I) immunohistochemistry for Ki67; scale bare: 10 µm. Western blot analysis for 
p-AMPK (J, upper panel) and p-mTOR (K, upper panel) normalized on respective total protein forms (middle panels) and actin (lower 
panels) of two representative tumors excided from control and metformin-treated mice.
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The in vitro anti-proliferative effect of metformin in 
preclinical models is obtained by using higher doses than 
those reached in diabetic patients [49], thus apparently 
limiting its potential use in cancer treatment. However, in 
some tissues, metformin can accumulate at concentrations 
several-times higher than those found in the bloodstream 
[50], as demonstrated for the adrenal gland and liver [51]. 
The adrenal gland is in fact one of the tissues expressing 
the highest levels of the organic cation transporters 1 (Oct 
1) and 3 (Oct 3) [52], which are responsible for metformin 
cellular uptake and for its high concentration in this organ 
[53]. Moreover, due to the high charge of the molecule, 
metformin specifically concentrates in mitochondria 
[36]. Thus, it is conceivable that the current metformin 
dosage used in T2D treatment, despite the micromolar 
levels reached in the plasma, could reach up to millimolar 
levels in actively absorbing organs, such as the adrenal 
cortex. We demonstrated a significant decrease in both 
tumor growth rate and H295R cell proliferation within the 
tumor mass in metformin-treated ACC xenografted mice, 
associated with an increase in AMPK and a decrease in 
mTOR phosphorylation similar to that observed for 
in vitro-treated H295R.  These results were obtained 
in vivo employing a metformin dosage very similar to that 
used in diabetic patients and in line with the literature on 
rodent tumor xenograft models [54, 55], supporting the 
hypothesis of metformin concentration in the ACC tumor.
Several clinical trials, specifically designed with 
endpoints and outcomes allowing exploration of the anti-
cancer properties of metformin, are currently ongoing 
[https://clinicaltrials.gov]. They will also serve to clarify 
the doses at which metformin exerts its anti-cancer effects 
compared with its anti-diabetic properties. Further studies 
are necessary to evaluate a possible combined therapy with 
mitotane, also proven to affect mitochondrial function in 
H295R [56, 57], to reduce the dosage of both drugs together.
In conclusion, our findings provide the first 
preclinical report on the anti-proliferative and pro-
apoptotic effect of metformin in ACC and help to 
elucidate the intracellular signaling pathways involved. 
Mitochondrial functions and integrity are also the 
key targets for the anti-cancer activity of this drug in 
adrenocortical cancer cells. Further studies are necessary 
to validate these findings in vivo and better clarify the 
intracellular mechanisms involved in metformin activity, 
whilst proposing the prospective use of metformin in 
adrenocortical cancer therapy.
MATERIALS AND METHODS
Reagents
Primary antibodies directed against phospho-
Thr172-AMPKα1/2 (sc-33524), Actin (sc-1615), IGF-1Rβ 
(sc-713) were from Santa Cruz Biotechnology, Inc. (Santa 
Cruz, CA, USA); anti-AMPK-α, anti-phospho-p44/42 
ERK1/2 (Thr202/Tyr204), anti-p44/42 ERK1/2, anti-
Bcl-xl and anti-mTOR antibodies were from Cell 
Signaling Technology, Inc. (Danvers, Mass, USA); anti-
phospho-Ser2448-mTOR (09-213), and anti-Caspase 3 
(AB1899) antibodies were from Merck-Millipore 
(Darmstadt, Germany). Peroxidase-conjugated secondary 
antibodies, media and sera for cell cultures and metformin 
were from Sigma-Aldrich (Milan, Italy). Plastic ware 
was obtained from Corning (Milan, Italy). MTS solution 
(CellTiter96® Aqueous One Solution Cell proliferation 
assay) was from Promega (Madison, WI, USA). [3H]-
thymidine and 2-deoxy-[3H] D-glucose were provided 
by Perkin Elmer (Waltham, Massachusetts, USA). Other 
reagents for cell culture and microscopy were obtained 
from Sigma-Aldrich (Milan, Italy), except where specified.
Cell cultures
Human ACC cell lines H295R and SW13 were 
obtained from the American Type Culture Collection 
(Manassas, VA, USA) and used under passage 20. 
SW13 were cultured in DMEM/F-12 medium (Sigma-
Aldrich) with 10% FBS, 2 mM L-glutamine, 100 U/ml 
penicillin-100 μg/ml streptomycin, which was further 
enriched with a mixture of insulin/transferrin/selenium 
(Sigma-Aldrich) for H295R culturing. Cells were 
incubated at 37°C in a humidified 5% CO2 atmosphere.
MTS assay
H295R and SW13 cells seeded in 96-well plates 
(1 × 104 and 2.5 × 103 cells/well, respectively) were 
24-hour starved and treated in 10% FBS-medium with 
vehicle (control) or increasing metformin doses for the 
indicated time points. Media were replaced every three 
days. Cell viability was assessed by MTS assay, according 
to the manufacturer’s instructions, and analyzed by an 
ELISA plate reader (Wallac 1420, PerkinElmer, Monza, 
Italy) at 490 nm wavelength to measure optical density 
(OD). Each experimental point was performed in six 
replicates in at least three independent experiments.
Viable cell count 
H295R cells seeded in 12-well plates (1 × 105 cells/
well) were 24 h-starved and treated in 10% FBS-medium 
with vehicle (control) or increasing doses of metformin for 
the indicated time points. At each time point, cells were 
trypsinized and counted by a haemocytometer, after dead 
cell exclusion with trypan blue staining. The mean cell 
number was obtained by counting four replicates in three 
different experiments.
DNA synthesis assay: [3H]-thymidine (TdR) 
incorporation 
DNA synthesis was evaluated according to the 
amount of [3H]TdR incorporated into trichloroacetic acid 
(TCA)-precipitated materials. Cells grown in 10% FBS-
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complete medium till 70% confluence, were starved for 
24 hours and treated with increasing doses of metformin 
for 6, 24, 48 hours, pulsing them with 0.5 µCi/ml [3H]
TdR (6.7 Ci/mmol) for 4 hours before halting proliferation 
in ice-cold 10% TCA. After washing in 5% TCA, cells 
were solubilized in 0.25 N NaOH and radioactivity 
was measured using a scintillation beta counter. Each 
experimental point was performed in four replicates in at 
least three independent experiments.
Glucose uptake measurement
H295R cells seeded in 12-well plates (1 × 105 cells/
well) and grown up to confluence, were washed twice with 
PBS and t incubated overnight in a serum free, low glucose 
medium (0.55 mM). Cells were treated in the absence 
(control) or presence of increasing doses of metformin 
for 24 hours. After PBS-wash, cells were incubated with 
Hepes buffer (140 mM NaCl, 20 mM Hepes-Na pH 7.4, 
2.5 mM MgSO4, 1 mM CaCl2, 5 mM KCl) containing 
2-deoxy-[3H]D-glucose [1μCi/μl] for 10 minutes at 37°C. 
After wash with cold PBS, cells were lysed in 100 mM 
NaOH for 1 hour at 37°C. Radioactivity was measured by 
a scintillation beta counter.
SDS-PAGE and western blot analysis
Treated cells were lysed in RIPA buffer (20 mM 
Tris, pH 7.4, 150 mM NaCl, 0.5% Triton-100, 1 mM 
Na3VO4, 1 mM PMSF) and, after protein measurement 
by Comassie method, equal amounts of proteins for 
each sample (30 µg) were separated by SDS–PAGE and 
transferred onto PVDF membranes (Immobilon, Merck 
Millipore). Each membrane was incubated overnight 
at 4°C with primary antibodies at the appropriate 
dilutions, then with peroxidase-secondary IgG (1:2000) 
at room temperature for 1 hour. Image acquisition and 
densitometric analysis were performed with Quantity 
One software on a ChemiDoc XRS instrument (BIO-
RAD Labs, CA, USA). All Western blots were repeated 
in at least 3 independent experiments. Actin was used as 
internal loading control to normalize protein expression.
Apoptotic evaluation by muse™ cytofluorimetric 
analysis
After 72 h treatment with increasing doses of 
metformin (0, 10, 20, 50 mM), H295R cells were 
trypsinized and analyzed with a Muse™ automated cell 
analyzer (Merck Millipore, Billerica, MA, USA) for 
apoptosis detection using the Muse™ Annexin V/Dead 
Cell (cat # MCH100105, Merck Millipore, Billerica, MA, 
USA) assay, according to the manufacturer’s instructions. 
Cells treated for 2 hours with 2 µM staurosporine were 
used as positive control for apoptosis induction.
Apoptosis antibody array
Cell lysates from H295R cells treated or untreated 
with 20 mM metformin for 48 hours were analyzed using 
a human apoptosis antibody array (RayBiotech, Norcross, 
GA, USA) according to the manufacturer’s instructions. 
Array spot emission images were captured by ChemiDoc 
XRS instrument (BIO-RAD Labs, CA, USA). 
Xenograft model for tumor growth assessment
Female athymic CD1 nude mice (9 week-old, 
Charles River Laboratories, Italy) were inoculated 
subcutaneously with H295R cell suspension (7 × 106 
cells/100 µl). Almost all H295R injected mice developed 
a detectable tumor except one (84% overall tumor take 
rate), confirming the aggressiveness of ACC derived cells. 
Tumor growth was monitored daily and once solid tumors 
reached a 5 mm mean diameter the animals were randomly 
assigned to intraperitoneal injection of metformin (3 mg in 
100 µl PBS/day, 6 days/week) or vehicle. Tumor volume 
(mm3) was monitored 3 times a week by two independent 
investigators and was calculated by using the following 
formula: length x width2/2. Anti-tumor activity of the 
drug was evaluated in terms of tumor growth inhibition 
percentage, calculated by 1-Treated/Control tumor volume 
ratios (1-T/C) [58]. Data were expressed as mean ± SE.
Drug tolerability in tumor-bearing mice was 
assessed in terms of: a) lethal toxicity, i.e. any death in 
treated mice occurring before any death in control mice; b) 
body weight loss percentage = 100 – (body weight on day 
x/body weight on day 1) × 100, where x represents a day 
after or during the treatment period [58].
Animal studies were performed in compliance 
with an institutionally approved protocol and with the 
National Institutes of Health Guide for the Care and Use 
of Laboratory Animals.
Histological and immunohistochemical 
examination of xenografts 
Tissues were fixed in 10% buffered formalin and 
paraffin-embedded. Five-micrometer sections were 
hematoxylin and eosin (H/E) stained for histologic 
evaluation or used for immunohistochemistry. 
Immunohistochemical analysis with mouse anti-human 
Ki-67 monoclonal (Dako, Glostrup, Denmark) was 
performed with the Ventana Benchmark XT system 
(Ventana Medical Systems, Tucson, AZ, USA). Nuclei were 
hematoxylin counterstained. Ki-67 positive nuclei were 
counted on 1000 tumor cells in 3 tumors for each group. 
Negative controls were performed by omitting the primary 
antibodies. Immunohistochemical analysis with rabbit anti-
human SF-1 polyclonal IgG (Upstate, Charlottesville, VA) 
was performed with the Ventana Benchmark XT system 
(Ventana Medical Systems, Tucson, AZ, USA).
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Statistical analysis
Statistical analysis was performed using SPSS 
22.0 software (SPSS Inc. Chicago, IL, USA). The 
Kolmogorov–Smirnov test was used to verify the normal 
distribution of data which were then expressed as mean 
± SE. One way ANOVA followed by post-hoc Dunnett’s 
test was applied for multiple comparisons, while Student’s 
t test was employed for comparing the two classes of 
data shown in figures. A P < 0.05 value was considered 
statistically significant. The half Inhibitory Concentration 
(IC50) of metformin was calculated on cell count, MTS 
and thymidine-incorporation dose-response curves using 
Origin software 6.1 version (OriginLab Corporation, 
Northampton, MA).
ACKNOWLEDGMENTS
We thank Prof. Paola Chiarugi, Dr. Giuseppe 
Castronovo, Dr. Tommaso Mello and Dr. Niccolò 
Bartalucci (University of Florence) for providing the anti-
phospho AMPK, anti-Caspase 3, anti-mTOR and anti-Bcl-
xl antibodies, respectively.
CONFLICTS OF INTEREST
The authors declare no conflicts of interest 
R. Armignacco, G. Cantini, L. Canu, M. Luconi, M. 
Mannelli, G. Nesi, G. Poli are members of the ENS@T 
(European Network for the Study of Adrenal Tumours).
FUNDINGS
The research leading to these results received 
funding from the Seventh Framework Programme 
(FP7/2007-2013) under grant agreement n° 259735 
ENS@T-Cancer; from the FIRB fund of the Italian 
Minister of University, Research and Instruction (prot 
number: RBAP1153LS); from Associazione Italiana 
Ricerca sul Cancro AIRC (prot. IG2015-17691).  
REFERENCES 
1. Terzolo M, Angeli A, Fassnacht M, Daffara F, 
Tauchmanova L, Conton PA, Rossetto R, Buci L, Sperone P, 
Grossrubatscher E, Reimondo G, Bollito E, Papotti M, et al. 
Adjuvant mitotane treatment for adrenocortical carcinoma. 
N Engl J Med. 2007;356:2372–80. 
2. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, 
Berruti A, Welin S, Schade-Brittinger C, Lacroix A, 
Jarzab B, Sorbye H, Torpy DJ, Stepan V, et al. and FIRM-
ACT Study Group. Combination chemotherapy in advanced 
adrenocortical carcinoma. N Engl J Med. 2012;366:2189–97.
3. D’Avolio A, De Francia S, Basile V, Cusato J, De Martino F, 
Pirro E, Piccione F, Ardito A, Zaggia B, Volante M, Di 
Perri G, Terzolo M. Influence of the CYP2B6 polymorphism 
on the pharmacokinetics of mitotane. Pharmacogenet 
Genomics. 2013;23:293–300. 
 4. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, 
Morris AD. Metformin and reduced risk of cancer in 
diabetic patients. BMJ. 2005;330:1304–5. 
 5. Decensi A, Puntoni M, Goodwin P, Cazzaniga M, 
Gennari A, Bonanni B, Gandini S. Metformin and cancer 
risk in diabetic patients: a systematic review and meta-
analysis. Cancer Prev Res (Phila). 2010; 3:1451–61. 
 6. Johnson JA, Bowker SL. Intensive glycaemic control and 
cancer risk in type 2 diabetes: a meta-analysis of major 
trials. Diabetologia. 2011; 54:25–31.
 7. Monami M, Colombi C, Balzi D, Dicembrini I, Giannini S, 
Melani C, Vitale V, Romano D, Barchielli A, Marchionni N, 
Rotella CM, Mannucci E. Metformin and cancer occurrence 
in insulin-treated type 2 diabetic patients. Diabetes Care. 
2011; 34:129–31. 
 8. Pollak M. Potential applications for biguanides in oncology. 
J Clin Invest. 2013; 123:3693–700.
 9. Quinn BJ, Kitagawa H, Memmott RM, Gills JJ, Dennis PA. 
Repositioning metformin for cancer prevention and 
treatment. Trends Endocrinol Metab. 2013; 24:469–80. 
10. Karnevi E, Said K, Andersson R, Rosendahl AH. 
Metformin-mediated growth inhibition involves 
suppression of the IGF-I receptor signalling pathway in 
human pancreatic cancer cells. BMC Cancer. 2013; 13:235. 
11. Cantini G, Lombardi A, Piscitelli E, Poli G, Ceni E, 
Marchiani S, Ercolino T, Galli A, Serio M, Mannelli M, 
Luconi M. Rosiglitazone inhibits adrenocortical cancer cell 
proliferation by interfering with the IGF-IR intracellular 
signaling. PPAR Res. 2008; 2008:904041. 
12. Doghman M, El Wakil A, Cardinaud B, Thomas E, 
Wang J, Zhao W, Peralta-Del Valle MH, Figueiredo BC, 
Zambetti GP, Lalli E. Regulation of insulin-like growth 
factor-mammalian target of rapamycin signaling by 
microRNA in childhood adrenocortical tumours. Cancer 
Res. 2010; 70:4666–75.
13. Doghman M, Lalli E. Efficacy of the novel dual PI3-kinase/
mTOR inhibitor NVP-BEZ235 in a preclinical model of 
adrenocortical carcinoma. Mol Cell Endocrinol. 2012; 
364:101–4. 
14. De Martino MC, Feelders RA, de Herder WW, van 
Koetsveld PM, Dogan F, Janssen JA, Waaijers AM, 
Pivonello C, Lamberts SW, Colao A, de Krijger RR, 
Pivonello R, Hofland LJ. Characterization of the mTOR 
pathway in human normal adrenal and adrenocortical 
tumours. Endocr Relat Cancer. 2014; 21:601–13. 
15. Luconi M, Mangoni M, Gelmini S, Poli G, Nesi G, 
Francalanci M, Pratesi N, Cantini G, Lombardi A, Pepi M, 
Ercolino T, Serio M, Orlando C, et al. Rosiglitazone impairs 
proliferation of human adrenocortical cancer: preclinical 
study in a xenograft mouse model. Endocr Relat Cancer. 
2010; 17:169–77.
Oncotarget12www.impactjournals.com/oncotarget
16. Luconi M, Mannelli M. Xenograft models for preclinical 
drug testing: implications for adrenocortical cancer. Mol 
Cell Endocrinol. 2012; 351:71–7. 
17. Pollak M. The insulin and insulin-like growth factor 
receptor family in neoplasia: an update. Nat Rev Cancer. 
2012; 12:159–69. 
18. Mohammed A, Janakiram NB, Brewer M, Ritchie RL, 
Marya A, Lightfoot S, Steele VE, Rao CV. Antidiabetic 
Drug Metformin Prevents Progression of Pancreatic 
Cancer by Targeting in Part Cancer Stem Cells and mTOR 
Signaling. Transl Oncol. 2013; 6:649–59. 
19. Rozengurt E, Sinnett-Smith J, Kisfalvi K. Crosstalk 
between insulin/insulin-like growth factor-1 receptors and 
G protein-coupled receptor signaling systems: a novel target 
for the antidiabetic drug metformin in pancreatic cancer. 
Clin Cancer Res. 2010; 16:2505–11. 
20. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, 
Pollak M. Metformin is an AMP  kinase-dependent 
growth inhibitor for breast cancer cells. Cancer Res. 2006; 
66:10269–73.
21. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, 
Sonenberg N. Metformin inhibits mammalian target of 
rapamycin-dependent translation initiation in breast cancer 
cells. Cancer Res. 2007; 67:10804–12.
22. Sarfstein R, Friedman Y, Attias-Geva Z, Fishman A, 
Bruchim I, Werner H. Metformin downregulates the insulin/
IGF-I signaling pathway and inhibits different uterine 
serous carcinoma (USC) cells proliferation and migration in 
p53-dependent or -independent manners. PLoS One. 2013 
Apr 19; 8:e61537. 
23. Xie Y, Wang JL, Ji M, Yuan ZF, Peng Z, Zhang Y, Wen JG, 
Shi HR. Regulation of  insulin-like growth factor signaling 
by metformin in endometrial cancer cells. Oncol Lett. 2014; 
8:1993–1999. 
24. Kato H, Sekine Y, Furuya Y, Miyazawa Y, Koike H, 
Suzuki K. Metformin inhibits the proliferation of human 
prostate cancer PC-3 cells via the downregulation of 
insulin-like growth factor 1 receptor. Biochem Biophys Res 
Commun. 2015; 461:115–21.
25. Salani B, Maffioli S, Hamoudane M, Parodi A, Ravera S, 
Passalacqua M, Alama A, Nhiri M, Cordera R, Maggi D. 
Caveolin-1 is essential for metformin inhibitory effect on 
IGF1 action in non-small-cell lung cancer cells. FASEB J. 
2012; 26:788–98. 
26. Gicquel C, Raffin-Sanson ML, Gaston V, Bertagna X, 
Plouin PF, Schlumberger M, Louvel A, Luton JP, Le 
Bouc Y. Structural and functional abnormalities at 11p15 
are associated with the malignant phenotype in sporadic 
adrenocortical tumours: study on a series of 82 tumours. 
J Clin Endocrinol Metab. 1997; 82:2559–65.
27. Logié A, Boulle N, Gaston V, Perin L, Boudou P, Le 
Bouc Y, Gicquel C. Autocrine role of IGF-II in proliferation 
of human adrenocortical carcinoma NCI H295R cell line. 
J Mol Endocrinol. 1999; 23:23–32.
28. Kirschner LS. The next generation of therapies for 
adrenocortical cancers. Trends Endocrinol Metab. 
2012;23:343–50.
29. Schayek H, Bentov I, Rotem I, Pasmanik-Chor M, 
Ginsberg D, Plymate SR, Werner H. Transcription factor 
E2F1 is a potent transactivator of the insulin-like growth 
factor-I receptor (IGF-IR) gene. Growth Horm IGF Res. 
2010; 20:68–72. 
30. Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, 
Thor AD. Metformin inhibits breast cancer cell growth, 
colony formation and induces cell cycle arrest in vitro. Cell 
Cycle. 2009; 8:909–15. 
31. Ferruzzi P, Ceni E, Tarocchi M, Grappone C, 
Milani S, Galli A, Fiorelli G, Serio M, Mannelli M. 
Thiazolidinediones inhibit growth and invasiveness of 
the human adrenocortical cancer cell line H295R. J Clin 
Endocrinol Metab. 2005; 90:1332–9. 
32. Betz MJ, Shapiro I, Fassnacht M, Hahner S, Reincke M, 
Beuschlein F; German and Austrian Adrenal Network. 
Peroxisome proliferator-activated receptor-gamma agonists 
suppress adrenocortical tumour cell proliferation and induce 
differentiation. J Clin Endocrinol Metab. 2005; 90:3886–96.
33. Tosca L, Ramé C, Chabrolle C, Tesseraud S, Dupont J. 
Metformin decreases IGF1-induced cell proliferation and 
protein synthesis through AMP-activated protein kinase 
in cultured bovine granulosa cells. Reproduction. 2010; 
139:409–18.
34. Kumar A, Al-Sammarraie N, DiPette DJ, Singh US. 
Metformin impairs Rho GTPase signaling to induce 
apoptosis in neuroblastoma cells and inhibits growth of 
tumours in the xenograft mouse model of neuroblastoma. 
Oncotarget. 2014 Nov; 5:11709–22. 
35. Brenner D, Mak TW. Mitochondrial cell death effectors. 
Curr Opin Cell Biol. 2009; 21:871–7
36. Owen MR, Doran E, Halestrap AP. Evidence that metformin 
exerts its anti-diabetic effects through inhibition of complex 
1 of the mitochondrial respiratory chain. Biochem J. 2000; 
348 Pt 3:607–14.  
37. Luengo A, Sullivan LB, Heiden MG. Understanding 
the complex-I-ty of metformin action: limiting 
mitochondrial respiration to improve cancer therapy. 
BMC Biol. 2014; 12:82.
38. Gwinn DM, Shackelford DB, Egan DF, Mihaylova MM, 
Mery A, Vasquez DS, Turk BE, Shaw RJ. AMPK 
phosphorylation of raptor mediates a metabolic checkpoint. 
Mol Cell. 2008; 30:214–26. 
39. Janzer A, German NJ, Gonzalez-Herrera KN, Asara JM, 
Haigis MC, Struhl K. Metformin and phenformin deplete 
tricarboxylic acid cycle and glycolytic intermediates during 
cell transformation and NTPs in cancer stem cells. Proc 
Natl Acad Sci U S A. 2014; 111:10574–9.
40. Faubert B, Boily G, Izreig S, Griss T, Samborska B, 
Dong Z, Dupuy F, Chambers C, Fuerth BJ, Viollet B, 
Oncotarget13www.impactjournals.com/oncotarget
Mamer OA, Avizonis D, De Berardinis RJ, et al. AMPK is 
a negative regulator of the Warburg effect and suppresses 
tumour growth in vivo. Cell Metab. 2013; 17:113–24.
41. De Martino MC, van Koetsveld PM, Pivonello R, 
Hofland LJ. Role of the mTOR pathway in normal and 
tumoural adrenal cells. Neuroendocrinology. 2010; 92 
Supplymentary 1:28–34. 
42. Winter JN, Fox TE, Kester M, Jefferson LS, Kimball SR. 
Phosphatidic acid mediates activation of mTORC1 through 
the ERK signaling pathway. Am J Physiol Cell Physiol. 
2010; 299:C335–44. 
43. Duong MT, Akli S, Wei C, Wingate HF, Liu W, Lu Y, 
Yi M, Mills GB, Hunt KK, Keyomarsi K. LMW-E/CDK2 
deregulates acinar morphogenesis, induces tumourigenesis, 
and associates with the activated b-Raf-ERK1/2-mTOR 
pathway in breast cancer patients. PLoS Genet. 2012; 
8:e1002538.
44. Muscella A, Vetrugno C, Calabriso N, Cossa LG, De 
Pascali SA, Fanizzi FP, Marsigliante S. [Pt(O,O’-acac)
(γ-acac)(DMS)] alters SH-SY5Y cell migration and 
invasion by the inhibition of Na+/H+ exchanger isoform 
1 occurring through a PKC-ε/ERK/mTOR Pathway. PLoS 
One. 2014; 9:e112186. 
45. Calderwood SK, Gong J. Heat Shock Proteins Promote 
Cancer: It’s a Protection Racket. Trends Biochem Sci. 
2016. pii: S0968–0004(16)00018–9. doi: 10.1016/j.
tibs.2016.01.003. [Epub ahead of print].
46. Wang C, Zhang Y, Guo K, Wang N, Jin H, Liu Y, Qin W. 
Heat shock proteins in hepatocellular carcinoma: Molecular 
mechanism and therapeutic potential. Int J Cancer. 2016; 
138:1824–34.
47. Poli G, Ceni E, Armignacco R, Ercolino T, Canu L, 
Baroni G, Nesi G, Galli A, Mannelli M, Luconi M. 
2D-DIGE proteomic analysis identifies new potential 
therapeutic targets for adrenocortical carcinoma. 
Oncotarget. 2015; 6:5695–706. 
48. Garrido C, Brunet M, Didelot C, Zermati Y, Schmitt E, 
Kroemer G. Heat shock proteins 27and70:anti-apoptotic 
protein swith tumourigenic properties. Cell Cycle. 2006; 
5:2592–2601
49. Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong 
JK, Furlong TJ, Greenfield JR, Greenup LC, Kirkpatrick CM, 
Ray JE, Timmins P, Williams KM. Clinical pharmacokinetics 
of metformin. Clin Pharmacokinet. 2011; 50:81–98.
50. Wilcock C, Bailey CJ. Accumulation of metformin by 
tissues of the normal and diabetic mouse. Xenobiotica. 
1994; 24:49–57.
51. Shingaki T, Hume WE, Takashima T, Katayama Y, Okauchi T, 
Hayashinaka E, Wada Y, Cui Y, Kusuhara H, Sugiyama Y, 
Watanabe Y. Quantitative Evaluation of mMate1 Function 
Based on Minimally Invasive Measurement of Tissue 
Concentration Using PET with [(11)C] Metformin in Mouse. 
Pharm Res. 2015; 32:2538–47.
52. Nies AT, Koepsell H, Winter S, Burk O, Klein K, Kerb R, 
Zanger UM, Keppler D, Schwab M, Schaeffeler E. 
Expression of organic cation transporters OCT1 (SLC22A1) 
and OCT3 (SLC22A3) is affected by genetic factors and 
cholestasis in human liver. Hepatology. 2009; 50:1227–40.
53. Beckmann R. [Absorption, distribution in the organism and 
elimination of metformin]. Diabetologia. 1969; 5:318–24. 
54. Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, 
Colosetti P, Auberger P, Tanti JF, Le Marchand-Brustel Y, 
Bost F. The antidiabetic drug metformin exerts an 
antitumoral effect in vitro and in vivo through a decrease of 
cyclin D1 level. Oncogene. 2008; 27:3576–86.
55. Lonardo E, Cioffi M, Sancho P, Sanchez-Ripoll Y, 
Trabulo SM, Dorado J, Balic A, Hidalgo M, Heeschen C.
Metformin targets the metabolic achilles heel of human 
pancreatic cancer stem cells. PLoS One. 2013; 8:e76518. 
56. Poli G, Guasti D, Rapizzi E, Fucci R, Canu L, Bandini A, 
Cini N, Bani D, Mannelli M, Luconi M. Morphofunctional 
effects of mitotane on mitochondria in human adrenocortical 
cancer cells. Endocr Relat Cancer. 2013 Jun 27; 20:537–50.
57. Hescot S, Slama A, Lombès A, Paci A, Remy H, Leboulleux  S, 
Chadarevian R, Trabado S, Amazit L, Young J, Baudin E, 
Lombès M. Mitotane alters mitochondrial respiratory chain 
activity by inducing cytochrome c oxidase defect in human 
adrenocortical cells. Endocr Relat Cancer. 2013; 20:371–81.
58. Hollingshead MG 2008 Antitumour efficacy testing in 
rodents. Journal of the National Cancer Institute 2008; 
100:1500–1510.
